MicroRNA 1207 (miR-1207)

MicroRNA 1207 (miR-1207) is a small, non-coding RNA molecule involved in the post-transcriptional regulation of gene expression in multicellular organisms[2]. It is transcribed by RNA polymerase II as part of a primary transcript and processed into a mature miRNA that functions by incorporation into the RNA-induced silencing complex (RISC), where it guides target recognition through imperfect base pairing with mRNAs. This usually results in translational inhibition or degradation of the target mRNA[2]. miR-1207-3p, a variant of miR-1207, is notably overexpressed in aggressive forms of prostate cancer and is being investigated as a novel prognostic biomarker for disease progression and outcome[1]. Aberrant expression of this miRNA may contribute to racial disparities in prostate cancer aggressiveness and is associated with adverse clinicopathological features, including recurrence and poor prognosis[1]. miR-1207 is encoded by the PVT1 locus at 8q24, a known susceptibility locus for prostate cancer[1]. There is currently no validated drug directly targeting this miRNA, and its utility is primarily as a prognostic biomarker rather than as a direct therapeutic target at present[1][2].

Other names

hsa-mir-1207MIRN1207MIR1207miR-1207-3p